In this TLA S02 session, Damien Keogh explores why the real challenge in longevity may not be scientific discovery alone, but how the space is defined, measured, and evaluated. Drawing from drug discovery, venture capital, traditional Chinese medicine, evolutionary biology and AI, he offers a practical framework for separating vague longevity claims from truly actionable science - and makes the case that nature may already contain the molecules we are looking for.

Takeaways:
• Why many longevity claims sound exciting but fall apart when you ask for clear endpoints, mechanisms, and measurable benchmarks.
• How AI, polypharmacology, and natural-product research are opening new pathways for drug discovery and longevity science.
• Why the leaders and companies that define the standards of longevity may end up shaping the market itself.